Crestor vs Repatha: Cost, Access, and Clinical Value Compared

How These Two Drugs Actually Work

Rosuvastatin and evolocumab both lower LDL cholesterol, but they do so through entirely different biological pathways. That distinction shapes everything from cost to who qualifies for each drug.

Rosuvastatin belongs to the statin class. It blocks HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver, forcing hepatocytes to upregulate LDL receptors on their surface. The result: more circulating LDL gets pulled out of the bloodstream. At the 20 mg dose, rosuvastatin typically lowers LDL-C by 52% from baseline, making it one of the most potent statins available. It is taken as a daily oral tablet.

Evolocumab takes a different approach. It is a fully human monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9). Normally, PCSK9 tags LDL receptors on liver cells for degradation. By neutralizing PCSK9, evolocumab allows more LDL receptors to survive and recycle back to the cell surface, clearing LDL from the blood at a faster rate. In the FOURIER trial (N=27,564), adding evolocumab 140 mg every two weeks to statin therapy reduced LDL-C by an additional 59% compared to placebo. Patients self-inject using a prefilled autoinjector or syringe, either every two weeks or once monthly at the 420 mg dose.

The practical consequence: evolocumab is never used alone. It is designed to be layered on top of statin therapy. This means patients considering "Crestor vs Repatha" are usually not choosing between two interchangeable options. They are deciding whether a statin alone is enough or whether they need escalation.

Clinical Trial Evidence: JUPITER vs FOURIER

Both drugs have landmark cardiovascular outcomes data. But these trials enrolled different populations and measured different endpoints, so direct numerical comparisons require caution.

The JUPITER trial (2008) randomized 17,802 apparently healthy adults with LDL-C below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP ≥ 2.0 mg/L) to rosuvastatin 20 mg daily or placebo. The trial was stopped early at a median of 1.9 years because rosuvastatin produced a 44% reduction in the primary composite endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or confirmed cardiovascular death; HR 0.56 to 95% CI 0.46 to 0.69, P<0.00001) [1]. This was a primary prevention population.

The FOURIER trial (2017) enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) already receiving moderate- or high-intensity statin therapy. Adding evolocumab reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% over a median of 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [2]. The more clinically relevant secondary endpoint of cardiovascular death, MI, or stroke fell by 20% (HR 0.80, P<0.001).

These numbers cannot be stacked against each other in a simple "44% beats 15%" comparison. JUPITER tested rosuvastatin against no lipid therapy at all. FOURIER tested evolocumab on top of already-optimized statin treatment. The 15% reduction in FOURIER represents incremental benefit after statins have already captured the bulk of achievable risk reduction.

Dr. Robert Giugliano, a FOURIER investigator at Brigham and Women's Hospital, noted: "PCSK9 inhibitors are not replacements for statins. They address the residual risk that persists despite optimal statin therapy."

Cost Breakdown: The Numbers That Matter

This is where the two drugs diverge most dramatically. The price gap between a generic statin and a branded biologic is measured in orders of magnitude.

Rosuvastatin (generic Crestor): Brand-name Crestor lost U.S. patent exclusivity in 2016, and multiple generic manufacturers now produce rosuvastatin calcium tablets. The average retail cash price for a 30-day supply of generic rosuvastatin 20 mg ranges from $10 to $30 depending on pharmacy. With most commercial insurance plans, the copay sits between $0 and $15 because rosuvastatin occupies Tier 1 (preferred generic) status on nearly every formulary in the country. Medicare Part D plans cover it with minimal cost-sharing.

Evolocumab (Repatha): When Amgen launched Repatha in 2015, the list price was $14,100 per year. Following multiple rounds of competitive pressure (from alirocumab, biosimilar pipeline entries, and payer pushback), Amgen reduced the list price to approximately $6,168 per year, or $514 per month [3]. Even at the lowered price, out-of-pocket costs for patients vary widely. Commercial insurance copay assistance programs from Amgen can reduce the patient obligation to as little as $5 per month for eligible individuals. Without assistance, specialty tier copays can run $150 to $400 per month depending on the plan.

A 2020 Institute for Clinical and Economic Review (ICER) analysis estimated that the cost-effectiveness threshold price for PCSK9 inhibitors ranged from $2,300 to $3,400 per year at a willingness-to-pay of $100,000 per quality-adjusted life year (QALY). The current Repatha price of $6,168 still exceeds that threshold, though the gap has narrowed considerably from the original launch price.

On a per-unit-of-LDL-lowering basis, the economics are stark. Rosuvastatin 20 mg lowers LDL by roughly 55% at a cost of about $120 to $360 per year. Adding evolocumab to that statin lowers LDL an additional 59% at a cost of roughly $6,168 per year. The marginal cost per percentage point of LDL reduction is approximately 30 to 50 times higher with evolocumab than with rosuvastatin.

Insurance Coverage and Prior Authorization

Formulary placement determines real-world access more than list price does for most patients. The two drugs sit in completely different coverage tiers and face radically different approval pathways.

Rosuvastatin requires no prior authorization on any major U.S. commercial or government formulary. It is a preferred generic. A prescriber writes the script, a pharmacist fills it, and the patient pays a minimal copay. Total time from prescription to patient's hand: one pharmacy visit.

Repatha faces a multi-step prior authorization process on virtually every plan. The American College of Cardiology/American Heart Association 2018 cholesterol guidelines recommend PCSK9 inhibitors for patients with clinical ASCVD at very high risk whose LDL-C remains ≥ 70 mg/dL on maximally tolerated statin therapy plus ezetimibe [4]. Most insurers require documented evidence of all of the following before approving Repatha:

• Current use of a maximally tolerated high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg)
• Trial of ezetimibe added to the statin
• LDL-C still above goal (typically ≥ 70 mg/dL for ASCVD patients or ≥ 100 mg/dL for primary prevention with familial hypercholesterolemia)
• Documentation of statin intolerance if not on high-intensity statin, including trial of at least two different statins

The prior authorization turnaround ranges from 3 to 14 business days. Denial rates for initial PCSK9 inhibitor requests exceeded 50% in early post-launch data, though approval rates have improved as payers have adjusted step-therapy criteria [5]. Peer-to-peer appeals frequently overturn initial denials when clinical documentation is thorough.

Medicare Part D covers Repatha but applies specialty tier cost-sharing. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D (effective 2025) has meaningfully reduced patient exposure for Medicare beneficiaries on high-cost specialty drugs, bringing the effective annual out-of-pocket ceiling for Repatha well below prior levels.

Who Gets Rosuvastatin, Who Gets Evolocumab

The clinical decision about which drug a patient receives is rarely an either/or choice. It follows a stepwise algorithm defined by the 2018 ACC/AHA Multisociety Guideline on Management of Blood Cholesterol.

Rosuvastatin first-line candidates include adults aged 40 to 75 with LDL-C ≥ 70 mg/dL and either clinical ASCVD, diabetes, LDL-C ≥ 190 mg/dL, or a 10-year ASCVD risk ≥ 7.5%. This captures millions of Americans. The 2023 AHA Heart Disease and Stroke Statistics update estimated that over 92 million U.S. adults have some form of cardiovascular disease, and statin-eligible populations are among the largest treatment groups in medicine [6].

Evolocumab candidates represent a much narrower population: patients with heterozygous or homozygous familial hypercholesterolemia (HeFH/HoFH) who cannot reach LDL targets with oral therapy alone, and patients with established ASCVD at very high risk (defined as history of multiple major ASCVD events or one event plus multiple high-risk conditions) whose LDL-C remains ≥ 70 mg/dL despite maximally tolerated statin plus ezetimibe.

In practice, this means a patient might take rosuvastatin 40 mg plus ezetimibe 10 mg, recheck labs in 4 to 6 weeks, and still have an LDL of 85 mg/dL after a prior MI. That patient would meet criteria for evolocumab. The statin is not stopped. Evolocumab is added as a third agent.

For patients with true statin intolerance (confirmed by rechallenge with at least two statins at lowest doses), evolocumab may be used with or without ezetimibe as primary LDL-lowering therapy. But confirmed complete statin intolerance affects only 5% to 7% of patients who report statin-associated muscle symptoms in clinical practice [7].

Side Effect Profiles

The tolerability comparison favors rosuvastatin for most patients, though evolocumab carries a notably clean side effect record in trials.

Rosuvastatin's most common adverse effects mirror the statin class: muscle pain or weakness (myalgia) reported by 5% to 10% of patients in clinical practice (though placebo-controlled data from studies like HOPE-3 show rates closer to 5%), liver enzyme elevations in under 1%, and a modest increase in new-onset diabetes risk. The JUPITER trial found rosuvastatin increased physician-reported diabetes by 25% compared to placebo (3.0% vs 2.4% over 1.9 years), though the absolute excess risk was 0.6% [1].

Evolocumab's adverse event profile in FOURIER was remarkably similar to placebo. Injection-site reactions occurred in 2.1% of evolocumab patients vs 1.6% for placebo. Myalgia rates were comparable between groups. No signal for neurocognitive effects emerged, despite early theoretical concerns about very low LDL levels. The dedicated EBBINGHAUS cognitive substudy (N=1,974) found no difference in cognitive function between evolocumab and placebo groups over a median of 19 months [8].

The 2018 ACC/AHA guideline explicitly states: "Clinicians and patients can be reassured about the cognitive safety of lowering LDL-C to very low levels with the addition of a PCSK9 inhibitor to statin therapy" [4].

Biosimilars and the Future Cost Equation

The cost gap between these two drug classes is likely to narrow over the coming years, though the timeline remains uncertain.

Rosuvastatin's generic market is mature. Multiple manufacturers compete on price, and costs have stabilized at the $10 to $30 per month range. Little further price erosion is expected.

Evolocumab faces a different trajectory. Amgen's core Repatha patents extend through the mid-2030s for certain formulations, but biosimilar development programs for both evolocumab and alirocumab (Praluent) are underway. The first biosimilar PCSK9 inhibitors could reach the U.S. market in the late 2020s or early 2030s, with projected price reductions of 15% to 30% based on patterns observed with other biosimilar monoclonal antibodies.

Inclisiran (Leqvio), a small interfering RNA (siRNA) targeting PCSK9 synthesis rather than the circulating protein, received FDA approval in 2021. It is administered as a subcutaneous injection by a healthcare provider every six months after initial dosing. Novartis priced inclisiran at $3,250 per year, aiming to undercut the PCSK9 monoclonal antibodies on cost while offering the convenience of twice-yearly dosing. The ORION-10 trial (N=1,561) demonstrated a 52% LDL reduction from baseline at day 510 [9]. Cardiovascular outcomes data from the ongoing ORION-4 trial are expected in 2026.

For now, the practical cost comparison remains: generic rosuvastatin at $10 to $30/month vs. Repatha at approximately $514/month before copay assistance.

Practical Access Strategies for Patients

Patients and prescribers navigating the gap between these two tiers of therapy have several options to reduce barriers.

For rosuvastatin, cost is rarely a barrier. GoodRx and similar discount platforms consistently show prices below $15 for a 30-day supply without insurance. Walmart's $4 generic list includes rosuvastatin at some dose levels.

For Repatha, Amgen's copay card program covers up to $4,500 per year in out-of-pocket costs for commercially insured patients, often reducing the monthly copay to $5. Patients without commercial insurance can apply to Amgen's patient assistance program (Amgen Safety Net Foundation), which provides Repatha at no cost to qualifying individuals with household incomes at or below 400% of the federal poverty level. Specialty pharmacies affiliated with the patient's insurance plan handle fulfillment and can assist with prior authorization documentation.

The prescriber's role is to submit thorough prior authorization paperwork on the first attempt. Documented LDL values on maximally tolerated statin plus ezetimibe, a clear ASCVD history or FH diagnosis, and evidence of guideline-directed escalation significantly improve first-pass approval rates.

Patients with Medicare Part D now benefit from the $2,000 annual out-of-pocket spending cap, which took effect January 2025. For a patient whose Repatha was previously costing $300 or more per month out of pocket, this cap compresses exposure to roughly $167 per month across the year.